Novostia, a pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s development efforts and advance its clinical evidence base. The Board of Directors appoints Mrs. Soad El Ghazouani as the new Chief Executive Officer, effective immediately, succeeding Mr. Alain Barbal who will join the Board of Directors.
